Thus, identification of clinical risk factors of grade 4 CIN, such as pre-treatment hemoglobin >13 g/dL, ANC >4 × 103/mm3, and albumin >4.4 g/dL, and anthracycline-taxane combination regimen, may help choose a patient at the highest risk for developing grade 4 CIN for the effective and efficient use of G-CSFs. The gene discussed is ALB; the disease is cervical squamous intraepithelial neoplasia.